CliffBio
small molecule

ASCORBIC ACID

ASCORBIC ACID

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameASCORBIC ACID
Active ingredientASCORBIC ACID
Strength25,000MG/50ML (500MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.